Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE OTC Markets Group Inc.
NEW YORK, Jan. 10, 2014 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Epigenomics AG (OTCQX: EPGNY; Frankfurt Stock Exchange: ECX, Prime Standard), a German-American molecular diagnostics company developing and commercializing products for cancer screening and diagnosis, has chosen to have its American Depositary Receipts (ADRs) trade on OTCQX®, the best marketplace with qualified companies.
Epigenomics begins trading today on OTCQX International, a segment of the OTCQX marketplace reserved for high-quality non-U.S. companies that are listed on a qualified international exchange and provide their home country disclosure to U.S. investors. U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"We are pleased to welcome Epigenomics to our OTCQX marketplace," said R. Cromwell Coulson, President and CEO of OTC Markets Group. "As an international company with operations in Europe and the U.S., Epigenomics joins a host of global companies that have chosen OTCQX to increase their visibility and engagement with U.S. investors. We look forward to working with Epigenomics' management team as they continue to expand the company's presence in the U.S. market."
Thomas Taapken, CEO/CFO of Epigenomics AG, commented, "We are very happy to have our ADRs now trade on OTCQX alongside a large number of high quality international companies. As we move forward with our U.S. commercialization plans, this step will enable us to raise Epigenomics' visibility among U.S. investors."
BNY Mellon will serve as Epigenomics's Principal American Liaison ("PAL") on OTCQX, responsible for providing professional guidance on OTCQX requirements.
Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The company's lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S. and China. Epigenomics has operations in Europe and the U.S.
Epigenomics trades on the Frankfurt Stock Exchange under the symbol "ECX" and in the U.S. on OTCQX under the symbol "EPGNY," where each ADR represents five ordinary shares.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into marketplaces to better inform investors of opportunities and risks – OTCQX®, The Best Marketplace with Qualified Companies; OTCQB®, The Venture Stage Marketplace with U.S. Reporting Companies; and OTC Pink®, The Open Marketplace with Variable Reporting Companies. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.
OTC Link® ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
©2012 PR Newswire. All Rights Reserved.
2362 U.S. Hwy 11